NCT04176848View on ClinicalTrials.gov

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

September 15, 2022

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

CFI-400945

CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily

DRUG

Durvalumab

Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)

Trial Locations (5)

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University Health Network, Toronto

OTHER

lead

Canadian Cancer Trials Group

NETWORK